Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 3, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction notification rather than comprehensive financial performance.
Material Changes
The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan. This resulted in an increase in the notional allocation of Ordinary Share ADRs on December 29, 2006, at a price of $52.76 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Important Facts for Investors
- Transaction Date: December 29, 2006.
- Transaction Price: $52.76 per Ordinary Share ADR.
- Involved Parties: Dr. R G Greig and Mrs. C Bruck Slaoui.
- Nature of Event: Increase in notional allocation due to plan re-valuation, not a direct market purchase.